A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
Jiang L, Driedonks TAP, Jong WSP, Dhakal S, van den Berg van Saparoea HB, Sitaras I, Zhou R, Caputo C, Littlefield K, Lowman M, Chen M, Lima G, Gololobova O, Smith B, Mahairaki V, Richardson MR, Mulka KR, Lane AP, Klein SL, Pekosz A, Brayton CF, Mankowski JL, Luirink J, Villano JS, Witwer KW.
Jiang L, et al. Among authors: chen m.
bioRxiv [Preprint]. 2022 Feb 1:2021.06.28.450181. doi: 10.1101/2021.06.28.450181.
bioRxiv. 2022.
PMID: 35132418
Free PMC article.
Updated.
Preprint.